Table 1 Combination index (CI) and dose reduction index (DRI) of tivozanib and gefitinib combination in T98G and U87MG cells.

From: Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells

Concentrations (μM)

fa

T98G

CI

DRI

Tivozanib

Gefitinib

Tivozanib

Gefitinib

10

1

0.64

 

0.43

2.38

212.76

10

2

0.65

 

0.41

2.45

113.87

10

5

0.68

 

0.37

2.84

54.38

10

10

0.7

 

0.35

3.18

31.78

10

20

0.72

 

0.35

3.43

17.68

10

50

0.78

 

0.31

4.69

10.86

U87MG

10

1

0.43

 

0.72

1.49

21.99

10

2

0.47

 

0.67

1.65

12.4

10

5

0.49

 

0.75

1.76

5.35

10

10

0.57

 

0.74

2.2

3.44

10

20

0.66

 

0.76

2.95

2.4

10

50

0.86

 

0.55

6.73

2.47

  1. DRI represents the order of magnitude of dose reduction that is allowed in combination for a given degree of effect as compared with the dose of each drug alone. “fa” denotes fraction affected.
Back to article page